RTTNews | Jun 11, 2021 10:39AM EDT

10:39 Friday, June 11, 2021 (RTTNews.com) - Shares of Precigen, Inc. (PGEN) are climbing more than 12% Friday morning.

Thursday, Precigen ActoBio, a unit of Precigen, announced positive topline results from the Phase 1b/2a study of AG019 ActoBiotics for the treatment of recent-onset type 1 diabetes (T1D).

The company said primary endpoint of both the Phase 1b AG019 monotherapy and the Phase 2a AG019 combination therapy was met.

Data from the primary analysis were presented at the Federation of Clinical Immunology Societies (FOCIS) 2021 Virtual Annual Meeting.

The company plans to advance AG019 to assess the efficacy of prolonged treatment of oral AG019.

PGEN, currently at $7.84, has been trading in the range of $3.36- $11.10 in the last one year.

Read the original article on RTTNews ( https://www.rttnews.com/3201808/stock-alert-precigen-gains-12-on-positive-results-from-diabetes-drug-study.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved